Korea May Adopt Further Cost-Containment Steps Under 'Moon Jae-In Care' – IQVIA
Korea is expected to feel the pressure to introduce more drug cost-containment measures amid rapidly rising National Health Insurance expenditures, IQVIA predicts. In particular, expenses associated with implementation of 'Moon Jae-in Care' could erode NHI financial surpluses in the short-medium term.
You may also be interested in...
To trim the healthcare financial burden and boost the country’s national health insurance coverage as planned, South Korea will introduce a drug re-evaluation system to adjust prices of both novel and generic drugs, drawing a negative response from the pharma industry.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.